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The prognosis of dengue remains a challenge in the early, objective triage of patients with
dengue fever of differing severity. Circulating immuno-modulating proteins have brought new
possibilities as prognostic markers of severe dengue (SD). This systematic review is devoted to
understanding the potential utility of blood-based cytokines and chemokines as prognostication
markers of SD based on the current literature. PubMed and Embase were searched. Of 794
candidate articles, 685 abstracts were screened against our exclusion/inclusion criteria and 25
(3.6%) studies met the quality assessments. A total of 18 studies were retrospective
observational and 2 were prospective cohort studies. Elevated IL-10, up to day 7 of fever onset,
stood out as a candidate prognostic marker for SD using the 1997 and 2009 World Health
Organization (WHO) case definitions. IFNg was another potential prognostic marker of SD
(1997 WHO case definition), but its levels varied between studies. Significant heterogeneity in
methodologies and patient cohorts prevent ready application of IL-10 and IFNg as prognostic
markers to other dengue populations. Our results suggest that the current non-randomized
studies are delivering inconsistent messages and higher-quality studies, with consistent
methodologies and validation in independent patient cohorts, are needed to delineate
confounding variables. Major gaps identified were full accounting and transparency of sampling
days, dengue virus type, infection status and age group.
Introduction
Dengue is an emerging arboviral threat globally as its spread
and incidence is moving on an upward trajectory, infecting
some 390 million people yearly (Bhatt et al., 2013). Dengue
can be asymptomatic, or present as a self-limiting dengue
fever (DF), and in certain patient subsets the disease may pre-
cipitate into the severe, potentially life-threatening forms of
dengue – dengue haemorrhagic fever (DHF) and dengue
shock syndrome (DSS) or severe dengue (SD). In the 1997
World Health Organization (WHO) case definition, patients
were diagnosed as having DHF if they had fever, thrombocy-
topenia, bleeding and evidence of plasma leakage (hypoprotei-
naemia, change in haematocrit of more than 20% or clinical
fluid accumulation) (WHO, 1997). DSS has all the features of
DHF plus circulatory failure in the form of rapid and weak
pulse, and narrow pulse pressure (<20 mm Hg), or age-
specific hypotension and cold, clammy skin and restlessness.
In the 2009 WHO case definition, patients were diagnosed as
SD if they had severe plasma leakage, severe bleeding and
severe organ involvement (aspartate aminotransferase or ala-
nine aminotransferase1000 U/L, impaired consciousness, or
failure of heart and other organs) (WHO, 2009). Dengue can
be caused by any of the four dengue types of the genus Flavivi-
rus. The propensity to develop SD is plausibly brought about
by a number of factors, including heterologous secondary
dengue infection, dengue type, age or a combination of these
(Kyle & Harris, 2008; OhAinle et al., 2011). There are no
effective antiviral therapeutics to treat dengue and the current
most advanced vaccine has an imbalanced efficacy against the
four dengue types (Capeding et al., 2014; Wilder-Smith &
Massad, 2016). In view of this, early prognosis of SD, prefera-
bly less than 96 h from onset of fever, can guide patient triage,
allow informed clinical decisions, and reduce disease morbid-
ity and mortality.
The dynamic nature of dengue presents significant chal-
lenges in clinical management and on health services,
Three supplementary tables are available with the online Supplementary
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especially during an outbreak. Currently, routine haemato-
logical and biochemical measurements in dengue patients
collectively correlate poorly with eventual clinical outcome,
there are no tests to differentiate those who will have DF
from those who will progress to and deteriorate to SD. In
the absence of any effective treatment against the disease,
proper fluid management is critical. Guidelines produced
by the WHO list a number of warning signs to help inform
clinical decision making, but they all have poor specificity
resulting in large numbers being admitted unnecessarily
(Thein et al., 2013). Over-hospitalization of dengue patients
is contributed to in part by the inability to prognosticate
early in the febrile phase, and resulted in excessive hospitali-
zation rates and costs (Lee et al., 2013). The unpredictable
nature of outbreaks often overwhelms already fragile
health-care systems. Prognosis is also important for moni-
toring dengue patients who display probable warning signs
of health deterioration or complications that warrant fur-
ther investigation. A prognostic marker is defined as a clini-
cal or biological characteristic that is objectively measurable
and that provides information on the likely outcome of the
disease in an untreated individual (Hayes et al., 1998).
Faced with the limited utility of current methods of SD prog-
nosis, there has been interest in investigating the utility of sys-
temic soluble factors as potential markers of SD prognosis.
The two main prevailing hypotheses of DHF/DSS pathogene-
sis, antibody-dependent enhancement (ADE) and original
antigenic sin (or T cell immunopathology), centre on an
imbalanced immune system during secondary dengue infec-
tion (Halstead & O’Rourke, 1977; Mongkolsapaya et al., 2003)
triggering an exaggerated and imbalanced inflammatory cas-
cade (Srikiatkhachorn & Green, 2010). In addition to second-
ary infections, the waning maternally-derived anti-dengue
virus (DENV) IgG antibodies and/or an altered cytokine pro-
file may explain SD in infants with primary infections (Libraty
et al., 2009; Nguyen et al., 2004). Soluble factors emanating
from immune cells (T cells, B cells, macrophages, mast cells,
dendritic cells, etc.), platelets, stromal and endothelial cells in
the form of cytokines and chemokines act as signalling mole-
cules synergizing with one another to orchestrate cell growth
and proliferation, differentiation/maturation, and immunity;
hence, modulating host responses to infections (Fink et al.,
2006). Cytokines and chemokines are small proteins typically
ranging from 8 to 40 kDa, and in this review we broadly refer
to them as immuno-modulating proteins. Cytokines are
secreted proteins that play a role in cell signalling, in the
induction, inhibition and effector phases of immune and
inflammatory responses. Chemokines are a subset of small
cytokines that recruit and exert chemotactic migration of
other cells to a localized area to exert a variety of biological
effects, including inflammation and homeostasis. Immuno-
modulating protein profiles change with the clinical course of
dengue, differ between DF and SD (Kumar et al., 2012;
Rathakrishnan et al., 2012), and are believed to have direct
impact on the manifestations of increased vascular permeabil-
ity, plasma leakage and thrombocytopenia (Green & Roth-
man, 2006; Murphy & Whitehead, 2011). Immuno-
modulating proteins have been proposed to cause a shift from
the predominant TH1-type response in DF to the TH2-type in
severe DHF (Fink et al., 2006); because molecular signalling
seemingly precedes gross morphological or observable clinical
symptoms, the potential use of immuno-modulating proteins
as early prognostic markers is especially welcoming (Lee &
Ooi, 2013). However, studies in humans have resulted in var-
ied responses and remained conflicting, with no objective con-
solidation of data having taken place so far. Hence, this
systematic review aims to be a collection and summary of pri-
mary research articles that focuses on the ostensible utility of
soluble immuno-modulating markers for the prognosis of SD.
Results
Study selection
We ran searches on PubMed and Embase, and a total of 794
references were retrieved: PubMed (n=451) and Embase
(n=343). After excluding 109 duplicates, 685 records were
screened on the basis of title and abstract against our exclu-
sion/inclusion criteria, thereby identifying 54 potentially eligi-
ble records (Table S1, available in the online Supplementary
Material). Two studies were excluded because the main text
could not be retrieved or had incomplete methods. Another
30 records were excluded (4 low quality, 25 medium quality
and 1with ambiguous sampling time). Some of the studies
were further moderated based on empirical evidence leading
to six studies being downgraded and one study being
upgraded (Table S1). A total of 24 studies were identified as
eventual eligible articles of high quality. The study selection
flow chart is shown in Fig. 1. We restricted the search to
‘English’ language and ‘Human’ subjects. Three studies were
excluded despite good study design due to a lack of compari-
son to DHF/DSS or SD (medium to high quality). Detection
bias (blinding of outcome assessors) was relatively homoge-
neous across these non-randomized studies (NRS) and leaves
all studies at approximately the same level of risk of bias and,
thus, not considered.
Study characteristics
A total of 19 out of 24 studies were case–control studies
(Arias et al., 2014; Bozza et al., 2008; Brasier et al.,
2012; Butthep et al., 2012; Chen et al., 2005; Furuta et al.,
2012; Green et al., 1999a, b; Guerrero et al., 2013;
Houghton-Triviño et al., 2010; De La Cruz Hernandez
et al., 2014; Laur et al., 1998; Levy et al., 2010; Malavige
et al., 2013a; Nguyen et al., 2004; Del Moral-Hernandez
et al., 2014; Perez et al., 2004; Soundravally et al., 2014;
Wang et al., 2007), and the remaining 5 studies were pro-
spective cohort studies (de-Oliveira-Pinto et al., 2012;
Kumar et al., 2012; Kurane et al., 1991, 1993; Suharti et al.,
2003). Comparison groups were healthy controls, patients
with other febrile illness (OFI) or non-severe disease
patients (DF or non-SD); however, comparisons made
between SD and non-SD cases were considered most ideal
for the purpose of this review. Study characteristics of the
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24 studies are reported in Table 1. One study did not specify
which WHO case definition was applied, but this was veri-
fied with the authors and the manuscript was subsequently
accepted for further evaluation (de-Oliveira-Pinto et al.,
2012).
Ten studies noted affirmatively that their first blood sam-
pling was performed at the febrile phase, which we defined
here as <5 days or <96 h from fever onset (Brasier et al.,
2012; Butthep et al., 2012; Green et al., 1999a, b; Kumar
et al., 2012; De La Cruz Hernandez et al., 2014; Malavige
et al., 2013a; Perez et al., 2004; Soundravally et al., 2014;
Wang et al., 2007). The remaining studies had wider blood
sampling windows, ranging from 1 to 10 days from symp-
tom onset (Arias et al., 2014; Bozza et al., 2008; Chen et al.,
2005; de-Oliveira-Pinto et al., 2012; Guerrero et al., 2013;
Houghton-Triviño et al., 2010; Kurane et al., 1991, 1993;
Laur et al., 1998; Levy et al., 2010; Del Moral-Hernandez
et al., 2014; Nguyen et al., 2004; Suharti et al., 2003). A
majority of studies (21/24, 87.5%) employed ELISAs for
quantification of single cytokine/chemokine, or multiplexed
suspension bead immunoassays for broader profiling. Three
studies (12.5%) used cytometric bead arrays (Guerrero
et al., 2013; Houghton-Triviño et al., 2010; De La Cruz
Hernandez et al., 2014).
Assessment of study design eligibility and risk of
bias in individual studies
Table S2 summarizes the risk of study design eligibility and
bias of selected studies according to the Cochrane NRS
Methods group. First, all studies compared DHF, DSS or
SD with DF, dengue without warning signs (DwoWS) or
dengue with warning signs (DwWS) groups, as this was part
of our quality assessment criterion (Table 2). Therefore,
risk of bias in this item was negative. We considered the
risk related to retrospective design as moderate, because the
outcome assessments were retrospective and the generation
of the hypothesis was prospective. Detection risk was con-
sidered low because patients were categorized according to
canonical and accepted definitions of dengue severity clini-
cal symptoms (WHO, 1997, 2009) and not by patients’
preference or marker (assay) outcomes. One study applied
modified WHO guidelines (Bozza et al., 2008). However,
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Fig. 1. Flow diagram of the search and review process.
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we consider the confounding risk of prognostic factors
moderate to high, because the type of immune-modulator
under study was not uniform across the studies. A Kappa
index of 0.91 was derived between two reviewers (W. Y. L.
and Y.H. L.) suggesting substantial agreement.
Assessment of study design eligibility and risk of
bias across studies
In this systematic review, which summarized mostly obser-
vational NRS, bias due to outcome differences may have
arisen but we considered it as low to moderate as the usage
and application of WHO case definition guidelines were
enforced, and any potential differing opinions of disease
severity minimized. However, comparability between stud-
ies utilizing the 1986/1997 or 2009 WHO revised case classi-
fication over time may be affected since the overlap
between old and new case definitions are substantially dif-
ferent and as one or the other gains acceptance.
Prognostication marker candidates: WHO (1997)
DHF I–IV
WHO (1986)/WHO (1997) was the most commonly applied
case definition in the studies (20/24, 83%) (Table 1). Studies
differed in the types of immuno-modulating proteins investi-
gated, and the most frequently profiled cytokines and chemo-
kines were TNFa (12/20, 60%), IFNg (11/20, 55%), IL-6
(10/20, 50%), IL-10 (9/20, 45%), IL-4 (6/20, 30%) and
IFNa (3/20, 15%). Despite being the most investigated cyto-
kine, TNFa was significantly elevated in DHF patients in only
five studies (Houghton-Triviño et al., 2010; Levy et al., 2010;
Nguyen et al., 2004; Soundravally et al., 2014; Wang et al.,
2007), and one study found no statistical difference in TNFa
levels between DF and DHF patients (Laur et al., 1998). The
rest of studies reported no statistical difference or did not
detect TNFa. By contrast, IL-10 stood out as the cytokine for
which concentration was elevated in DHF relative to DF
patients consistently in seven studies utilizing the WHO
(1986)/WHO (1997) case definition (Table 3) (Brasier et al.,
2012; Butthep et al., 2012; Chen et al., 2005; Green et al.,
1999b; Houghton-Triviño et al., 2010; Nguyen et al., 2004;
Perez et al., 2004). The association of dengue severity with cir-
culating levels of IFNg was more heterogeneous (Table 4)
(Bozza et al., 2008; Butthep et al., 2012; Chen et al., 2005;
Kumar et al., 2012; Nguyen et al., 2004; Soundravally et al.,
2014). Three studies noted increased IFNg in DHF and/or
DSS patients relative to DF patients or healthy controls (Bozza
et al., 2008; Butthep et al., 2012; Nguyen et al., 2004), whereas
three studies noted decreased IFNg levels in DHF/DSS over
DF patients (Chen et al., 2005; Kumar et al., 2012; Soundra-
vally et al., 2014). Bozza et al. (2008) noted defervescence
phase IFNg levels in adults (age 15–73 years) were associated
with disease severity (odds ratio=1.138, 95%confidence inter-
val1.041 to 1.245, P=0.0046). However, Green et al. (1999a)
reported no significant difference in febrile IFNg between DF
and DHF paediatric patients. In congruence, in infants (age
<1 year), IFNg (together with IL-2, IL-4, IL-6, IL-10, TNFa)
could not differentiate DHF I/II from DHF III/IV (Nguyen
et al., 2004).
Prognostication marker candidates: WHO (1997)
DHF III/IV
One study looked specifically at immuno-modulatory
markers of predicting DSS (DHF III/IV) mortality (Suharti
et al., 2003). The study population was restricted to only
DENV3-infected paediatric patients who were diagnosed as
DSS in a prospective study. In the acute phase of dengue
infection, plasma IL-1Ra levels were significantly higher in
DSS non-survivors (n=7) compared to DSS survivors
(n=43; 802.2±566.4 vs 1566.9±675.6 pg ml 1, P=0.0005).
Multiple logistic regression identified IL-1Ra as having sig-
nificant association with mortality on the day of admission
(P=0.007).
Prognostication marker candidates: WHO (2009)
SD
Of the selected 24 studies, 4 studies (16.7%) employed the
WHO (2009) case definition (Arias et al., 2014; de-Oliveira-
Pinto et al., 2012; Guerrero et al., 2013; Malavige et al.,
2013a). Among them, one reported elevation in IL-10 (Mala-
vige et al., 2013a), congruent with the seven WHO (1997)
guideline-utilizing studies that reported elevations in IL-10 in
DHF patients (Table 3), and one study reported elevated IL-
10 levels in DwoWS, DwWS and SD patients compared to
controls (Guerrero et al., 2013). Two studies reported eleva-
tions in sST2 (IL-1RL1) (Arias et al., 2014; Guerrero et al.,
2013) in SD patients in levels above those of DwoWS and
DwWS (Arias et al., 2014; Guerrero et al., 2013). The same
studies reported increased IL-6 levels in SD and DwWS rela-
tive to patients with DwoWS. Elevations in TNFRI and
TNRFII in DwoWS, DwWS and SD (Arias et al., 2014) were
similar to those observed in DHF patients (Wang et al., 2007).
Discussion
Our systematic review of studies published from 1998 to
2014 evaluated cytokines and chemokines as potential early
markers to prognosticate the development of SD. We evalu-
ated and documented judgements about evidence quality
from NRS and incorporated this into reporting of differen-
tially changed cytokines and/or chemokines for outcomes
based on WHO (1986)/WHO (1997) or WHO (2009) den-
gue case definitions. Twenty-four studies were identified to
be of suitably high quality, but with major gaps in descrip-
tions of patient demographics, DENV types and infection
status (primary, secondary or tertiary infections). Although
a consensus has yet to emerge, IL-10 levels stood out as a
potential marker of SD (DHF and SD) that was significantly
increased regardless of age (range 1 month to 76 years) or
infection status (primary or secondary).
Eight studies utilizing WHO (1986)/WHO (1997) or WHO
(2009) case definitions demonstrated elevated IL-10 levels
in SD patients. Interestingly, several studies, including a
Y. H. Lee, W.-Y. Leong and A. Wilder-Smith
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recent publication, showed similar IL-10 levels between
patients with and without SD (Bozza et al., 2008; Cui et al.,
2016; Guerrero et al., 2013; Kumar et al., 2012). The reason
for this discrepancy is not entirely clear. IL-10 is an import-
ant anti-inflammatory cytokine and general suppressor of
immune reactions, inhibiting IL-1, IL-6, IL-10 itself, IL-12,
IL-18, CSF and TNFa, as well as inhibiting the synthesis of
IL-2, IL-3, GM-CSF, TNFa and IFN-g (D’Andrea et al.,
1993). IL-10 may contribute to disease severity through
NS1-induced IL-10 production by monocytes, which in
turn suppresses dengue-specific T cell responses (Adikari
et al., 2016; Malavige et al., 2013b). Notably, data from ani-
mal studies suggest that NS1 activates immunological cas-
cades in monocytes and macrophages leading to
the pathologies observed in SD (Chen et al., 2015; Mod-
hiran et al., 2015). In addition to its immunosuppressive
roles, IL-10 has recently been reported as a protective medi-
ator against plasma leakage and vascular dysfunction
(Cheng & Sharma, 2015). IL-10 is secreted by a variety of
cell types including CD4+ and CD8+ T cells, B cells, macro-
phages, monocytes, eosinophils and mast cells (O’Garra
& Vieira, 2007). Measurements of circulating levels of IL-10
reflect the sum total of IL-10 produced from all cells in the
body at any one point. Production of IL-10 may change
according to the predominant cell type specific to the day of
infection to regulate viral clearance immunopathology
(reviewed by Tsai et al., 2013b) as different immune cells
are invoked at different stages of dengue infections (Boon-
nak et al., 2008; Clyde et al., 2006). The timing of IL-10 pro-
duction is dynamic and varies throughout the disease
course, exemplified by IL-10 levels peaking around early
defervescence in DHF patients, but less so in DF patients
(Adikari et al., 2016; Butthep et al., 2012; Kumar et al.,
2012; Libraty et al., 2002a), suggesting that the biggest dif-
ference between DF and DHF patients may be observed
around the day of early defervescence. Mechanistically,
the intrinsic ADE of DENV infections may modulate the
severity of dengue via increased IL-10 production and sub-
sequent enhancement of the Suppressor of Cytokine Signal-
ling (SOCS) system (Chareonsirisuthigul et al., 2007;
Suhrbier & La Linn, 2003; Ubol et al., 2010). Furthermore,
in vitro studies suggest that in ADE-DENV infections, the
role of IL-10 changes in the early and later stages of infec-
tion from anti-viral to immunoregulation (Halstead et al.,
2010; Tsai et al., 2013b). Two studies noted significant ele-
vations in IL-10 and IFNg in DHF and DSS patients com-
pared to DF patients (P<0.01) (Butthep et al., 2012; Nguyen
et al., 2004), whereas one study showed elevated IL-10 levels
(DF 11.7±3.5 vs DHF 117.0±52.8 pg ml 1; P=0.03) but
decreased IFNg in DHF compared to DF (DF 130.2±16.9
vs DHF 84.2±12.6 pg ml 1; P=0.01) (Chen et al., 2005). By
contrast, three other studies reported increased IL-10 levels
in DHF patients, but no difference in IFNg between DF and
DHF patients (Brasier et al., 2012; Green et al., 1999a;
Houghton-Triviño et al., 2010). Note that these studies had
different sampling timings. In addition, we found no con-
sistent trend of any potential interactions between IL-10
with the following cytokines: IL-2, IL-6, IL-12 and TNFa.
This is congruent with other studies as cytokine changes are
often mixed in dengue infections in different populations
(Chaturvedi et al., 2000), with the exception of IL-10 as it is
shown in this systematic review. Collectively, the exact sam-
pling timing of IL-10 may be a critical aspect in determining
its maximal potential as a marker for SD prognosis.
The discrepancy of IFNg in the five studies could be due to
the rapid kinetics in its circulating levels, and depending on
which infection day blood was sampled and analysed
the IFNg levels could be different (Green et al., 1999a;
Libraty et al., 2002b; Nguyen et al., 2004). Reports from
humans and from animal models suggest that IFNg con-
trols infections through viral clearance and limiting virus
replication (Costa et al., 2012; Horras et al., 2011; Pal et al.,
2014; Shresta et al., 2004). Notably, dengue viral titres cor-
relate with disease severity (Endy et al., 2004; Vaughn et al.,
2000), but are plausibly influenced by DENV type and
infection status (Duyen et al., 2011). Levels of IFNg can be
attenuated by IL-10 through SOCS-3 blockage of STAT1-
IFNg receptor interaction in intrinsic ADE-DENV infection
(Chareonsirisuthigul et al., 2007; Ubol et al., 2010). Indeed,
the absence of IFNg in a mouse model of dengue led to pri-
mary dengue-infection-induced lethality (Costa et al.,
2012). Thus, depending on the infection status and DENV
type, in combination with timing of IL-10 production,
IFNg levels may be affected, leading to altered viral clear-
ance, prolonged infection and consequently determining
disease severity. IFNg levels peak before defervescence in
DHF patients and peak after defervescence in DF patients,
because of this the maximum difference in the febrile phase
of dengue suggests an advantage of using IFNg as an early
marker of SD. However, the implication and utility of IFNg
needs further study with properly defined sampling win-
dows and DENV types taken into consideration.
To our knowledge, this is the first systematic review of
immuno-modulating proteins as prognostic markers of SD
sequelae. Two earlier published reviews did not apply and jus-
tify quality assessments (Chaturvedi et al., 2000; Yacoub &
Wills, 2014). This is worth highlighting as the restriction of
studies according to a set of inclusion/exclusion criteria, and
the introduction of quality assessments, retained studies with
better-defined methodologies. Longitudinal studies, where
daily measurements of studied immuno-modulating proteins
are taken, may best capture the dynamic kinetics of these pro-
teins in dengue. Although a few immuno-modulating proteins
are potentially promising as prognostic markers, prospective
observation cohort trials, such as the one by International
Research Consortium on Dengue Risk Assessment, Manage-
ment, and Surveillance (IDAMS; https://ClinicalTrials.gov;
identifier: NCT01550016), may aid further endorsement of
the utility of an acute phase prognostic marker for SD. In
addition, immuno-modulating proteins, in reflecting the car-
dinal symptoms of SD, plasma leakage and thrombocytope-
nia, should be given research priority (Yacoub & Wills, 2014;
Zapata et al., 2014). One promising example is TNFa, which
was reported to induce endothelial cell apoptosis (Chen et al.,
2007) and was also noted in this review as an elevated
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cytokine in DHF. Other potential circulating markers of den-
gue severity, such as proteases (Koraka et al., 2010; St John
et al., 2013; van de Weg et al., 2014), soluble adhesion mole-
cules (Cardier et al., 2006) or metabolites (Cui et al., 2013,
2016), may show potential as alternative soluble prognostic
markers of SD, but face similar challenges in the extensive
demands of large study cohorts. Capturing soluble factors that
correlate and potentially foretell pathognomonic symptoms
may not only increase the specificity and sensitivity of prog-
nosing SD, but also avoid the non-specific ‘cytokine storms’
observed in other acute infectious diseases, such as influenza
and malaria (Clark, 2007).
There were several limitations in our review process. First,
there were inadequate reports on the details of patient demo-
graphics, DENV type and patients’ infection status (primary,
secondary or tertiary infection) in the studies. Inclusion of
such information may be necessary to understand why results
may be heterogeneous. Critically, sampling windows (days of
illness from onset of fever) were at times not documented, or
varied widely, sometimes even within the same study. Second,
endpoint measurements of these studies varied substantially,
differing in the types of immuno-modulating proteins under
study. Not all studies investigated the same type of immuno-
modulating proteins in relation to dengue severity. Further-
more, data presented in tables or figures in the published
manuscripts rarely report concentration means and/or
the range of the significantly different immuno-modulating
proteins. This severely limited any statistical estimation of
odds ratios, sensitivity and specificity of the prognosis marker
candidates and prevents meta-analysis. Such wide variability
in studies has been reported elsewhere (Potts & Rothman,
2008). Third, after strictly adhering to internal assessments of
the quality of the primary studies, further moderation led to
six studies being downgraded and one study being upgraded
(Table S1). A study may have scored as high quality but may
have been weighed down due to an unlisted criterion, for
example, large variation in the studied cytokines (Chen et al.,
2006). Although this could potentially introduce bias, we
included this empirical exercise to ensure retention or exclu-
sion of studies that were under- or over-ranked but still added
value to the review.
Conclusions
This systematic review provides the basis for future high-qual-
ity studies urgently required to identify key prognostic
immuno-modulating protein markers of SD. They should be
performed according to REMARK criteria (McShane et al.,
2005) to avoid the methodological deficiencies discovered in
this systematic review, mostly with substantial heterogeneity
in the study populations and prognostic endpoints. Studies in
larger population sizes should reflect in detail the study popu-
lation’s age, infection status and DENV types, with standardi-
zation on first sample collection timing (<96 h from fever
onset), detailed patient infection information and prognostic
endpoint measurements.
The use of soluble immuno-modulating proteins as prognos-
tic markers of SD remains under investigation and yet a con-
sensus marker or marker signature for prognosing SD is
desirable. Is this achievable? Current evidence suggests that
different patient subpopulations – age groups (adults vs chil-
dren vs geriatric), DENV types 1 to 4, and infection status –
respond differently to dengue infections (Hammond et al.,
2005; OhAinle et al., 2011; Tricou et al., 2011). Accordingly,
different markers may be needed to optimally prognose SD in
different patient subpopulations (Lee & Ooi, 2013), and
potentially aid the design of dengue vaccines.
Methods
Search strategy and data extraction
The primary literature search was conducted according to
PRISMA (Preferred Reporting Items for Systematic Reviews
Table 2. Quality assessment criteria matrix
Criterion Score
0 1 2
Study design (control, DF, DHF) Only control vs DF Control vs DHF, Control vs
DF or DF vs DHF
Timing of sampling (days) No or ambiguous description Full description Within acute phase of
infection (5 days)
Age No or ambiguous description Full description
Data collection No or ambiguous description Case–control or retrospective
cohort
Prospective cohort
Diagnostic criteria [WHO (1997) or WHO, (2009)] No or ambiguous description Full description
Inclusion/exclusion criteria No or ambiguous description Full description
Infection status No or ambiguous description Full description
DENV type No or ambiguous description Full description
Statistical analysis No or ambiguous description Full description
Data statistics (P value provision) No or ambiguous description Full description
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and Meta-Analyses) guidelines (Moher et al., 2009), via
PubMed and Embase databases, for original research
articles with restriction to human studies and English lan-
guage. The search terms used for both databases were as fol-
lowed: ‘dengue AND (Cytokine OR Chemokine) AND
(predict* OR prognos* OR correlat* OR associat* OR indi-
cat*)’. We designed search strategies as shown in Table 5.
Two independent reviewers (W.Y. L. and Y.H. L.) screened
the results to identify relevant literature based on titles and
abstracts (when available), followed by another evaluation
according to the inclusion and exclusion criteria. Articles with
reported epidemiology, clinical signs, laboratory parameters
and prognosis markers of SD outcome were included.
Our exclusion criteria included animal models, cell lines
(in vitro studies), ex vivo cell studies, vaccine or anti-viral
trials, genetic markers studies, studies without controls or
inappropriate controls and also review articles. Of note, this
review is devoted to the utility of human circulating cyto-
kines and chemokines as prognostication markers; hence,
other proteins such as immunoglobulins, acute phase pro-
teins and proteases were excluded. When both reviewers
(W. Y. L. and Y.H. L.) agreed on the final selected title and
abstracts, the full texts of the articles were obtained and
independently reviewed for eligibility.
Data extraction was performed by a single reviewer
(W. Y. L.) using a data extraction sheet and was checked by
another reviewer (Y. H. L.). The data extracted included the
name of first author, year of publication, age, gender, dis-
ease outcome – DF/DHF/DSS or DwoWS, DwWS and SD –
sample size, study design, location of study, specific markers
investigated and results of the analysis.
Risk of bias and quality assessment
Two reviewers (W. Y. L. and Y.H. L.) independently evalu-
ated the risk of bias in selected studies by assessing studies
according to a checklist developed by the Cochrane NRS
Methods group (Cochrane Group, 2012) as shown in
Table S3. Assessment of outcome was not masked in all
studies due to the need to diagnose dengue severity.
Subsequently, the quality of selected studies was assessed
across a matrix of ten metrics, namely (i) study design, (ii)
time of sampling, (iii) age, (iv) data collection, (v) diagnostic
criteria, (vi) inclusion/exclusion criteria, (vii) infection status,
(viii) DENV type, (ix) statistical analysis, (x) data statistics.
The quality assessment score system was based on a modified
version of the Newcastle–Ottawa scale (NOS) (Wells et al.,
2013) and is described in Table 2. The maximum score is 12,
and a score of 9–12 is considered as high quality, 5–8
as moderate quality and 1–4 as low quality. The measure of
agreement between the two reviewers (W.Y. L. and Y.H. L.)
was assessed using the Kappa index (MedCalc version 12.5).
None of the studies were randomized clinical trials and
Table 5. Electronic search strategy design
Databases and years
searched
Date searched and search files Number
retrieved
PubMed (1965–current) 1 Dengue [all fields] (13517)
2 Dengue [MESH terms] (7753)
3 1 OR 2 (13517)
4 Cytokine OR Chemokine [Text Word] (190750)
5 Cytokine [MESH terms] (545522)
6 Cytokine OR Chemokine [Title/Abstract] (173026)
7 4 OR 5 OR 6 (595542)
8 Biological markers [MESH terms] (642853)
9 Biomarker* OR bio-marker* OR marker* [Text Word] (754080)
10 Biomarker* OR bio-marker* OR marker* [Title/Abstract] (619463)
11 8 OR 9 OR 10 (1060932)
12 7 OR 11 (1515594)
13 predict* OR prognos* OR correlate* OR associat* OR indicat* [Text Word] (6348997)
14 predict* OR prognos* OR correlate* OR associat* OR indicat* [Title/Abstract] (6401251)
15 12 OR 13 (6674213)
16 3 AND 12 AND 15 (596)
17 Filter: English AND Human (451)
451
Embase (1974–current) 1 Exp dengue (12608)
2 Cytokine or Chemokine or Biological Marker or (Marker* or biomarker* or bio-marker*).tw.
(1014955)
3 predict* or prognos* or indicat* or associat* or correlat*.tw. (7851000)
4 1 AND 2 AND 3 (401)
5 Limit 5 to (human AND English language) (343)
343
TOTAL (include duplicates) 794
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because the studies were observational studies (case–control,
cohort), we assessed the quality of evidence using a list of ten
criteria modified from the NOS (Table 2), rather than Grad-
ing of Recommendations, Assessment, Development and
Evaluations (GRADE) (Guyatt et al., 2008).
Ascertainment of outcomes relied on WHO (1986), WHO
(1997) or WHO (2009) dengue case definition guidelines.
The WHO (1986) and WHO (1997) case definition guide-
lines were grouped together during analysis, but were ana-
lysed separately from the WHO (2009) case definition
guidelines due to reported differences (Leo et al., 2013; Nar-
vaez et al., 2011; Tsai et al., 2013a). There was the possibility
of bias or discrepancy in the classification of dengue sever-
ity; therefore, two reviewers (W. Y. L. and Y.H. L.) assessed
the studies either for explicit description of the WHO
guidelines used or for labelling of the groups’ categorization
(DF, DHF and DSS correspond to the WHO (1986)
and WHO (1997) case definitions, whereas non-SD, SD,
DwoWS and DwWS correspond to the WHO (2009) case
definition).
Odds ratios or statistical mean/median values could not be
identified in most studies. No pooling was done given the
extra sources of methodological diversity (types of prognos-
tic factors being measured) and bias. Hence, NRS are
expected to be more heterogeneous than randomized trials.
Acknowledgements
This work was supported by a research grant from the KK Women’s
and Children’s Hospital given to Y. H. L.
References
Adikari, T. N., Gomes, L., Wickramasinghe, N., Salimi, M.,
Wijesiriwardana, N., Kamaladasa, A., Shyamali, N. L., Ogg, G. S. &
Malavige, G. N. (2016).Dengue NS1 antigen contributes to disease severity
by inducing interleukin (IL)-10 by monocytes. Clin Exp Immunol 184, 90–
100.
Arias, J., Valero, N., Mosquera, J., Montiel, M., Reyes, E., Larreal, Y. &
Alvarez-Mon, M. (2014). Increased expression of cytokines, soluble cyto-
kine receptors, soluble apoptosis ligand and apoptosis in dengue. Virology
452–453, 42–51.
Bhatt, S., Gething, P. W., Brady, O. J., Messina, J. P., Farlow, A. W.,
Moyes, C. L., Drake, J. M., Brownstein, J. S., Hoen, A. G. & other
authors (2013). The global distribution and burden of dengue. Nature
496, 504–507.
Boonnak, K., Slike, B. M., Burgess, T. H., Mason, R. M., Wu, S. J.,
Sun, P., Porter, K., Rudiman, I. F., Yuwono, D. & other authors (2008).
Role of dendritic cells in antibody-dependent enhancement of dengue virus
infection. J Virol 82, 3939–3951.
Bozza, F. A., Cruz, O. G., Zagne, S. M., Azeredo, E. L., Nogueira, R. M.,
Assis, E. F., Bozza, P. T. & Kubelka, C. F. (2008). Multiplex cytokine
profile from dengue patients: MIP-1beta and IFN-gamma as predictive fac-
tors for severity. BMC Infect Dis 8, 86.
Brasier, A. R., Ju, H., Garcia, J., Spratt, H. M., Victor, S. S.,
Forshey, B. M., Halsey, E. S., Comach, G., Sierra, G. & other authors
(2012). A three-component biomarker panel for prediction of dengue
hemorrhagic fever. Am J Trop Med Hyg 86, 341–348.
Butthep, P., Chunhakan, S., Yoksan, S., Tangnararatchakit, K. &
Chuansumrit, A. (2012). Alteration of cytokines and chemokines during
febrile episodes associated with endothelial cell damage and plasma leakage
in dengue hemorrhagic fever. Pediatr Infect Dis J 31, e232–e238.
Capeding, M. R., Tran, N. H., Hadinegoro, S. R. S., Ismail, H. I. H. M.,
Chotpitayasunondh, T., Chua, M. N., Luong, C. Q., Rusmil, K.,
Wirawan, D. N. & other authors (2014). Clinical efficacy and safety of a
novel tetravalent dengue vaccine in healthy children in Asia: a phase 3,
randomised, observer-masked, placebo-controlled trial. Lancet 384, 1358–
1365.
Cardier, J. E., Rivas, B., Romano, E., Rothman, A. L., Perez-Perez, C.,
Ochoa, M., Caceres, A. M., Cardier, M., Guevara, N. & Giovannetti, R.
(2006). Evidence of vascular damage in dengue disease: demonstration of
high levels of soluble cell adhesion molecules and circulating endothelial
cells. Endothelium 13, 335–340.
Chareonsirisuthigul, T., Kalayanarooj, S. & Ubol, S. (2007). Dengue
virus (DENV) antibody-dependent enhancement of infection upregulates
the production of anti-inflammatory cytokines, but suppresses anti-DENV
free radical and pro-inflammatory cytokine production, in THP-1 cells.
J Gen Virol 88, 365–375.
Chaturvedi, U. C., Agarwal, R., Elbishbishi, E. A. & Mustafa, A. S.
(2000). Cytokine cascade in dengue hemorrhagic fever: implications for
pathogenesis. FEMS Immunol Med Microbiol 28, 183–188.
Chen, R. F., Liu, J. W., Yeh, W. T., Wang, L., Chang, J. C., Yu, H. R.,
Cheng, J. T. & Yang, K. D. (2005). Altered T helper 1 reaction but not
increase of virus load in patients with dengue hemorrhagic fever. FEMS
Immunol Med Microbiol 44, 43–50.
Chen, L. C., Lei, H. Y., Liu, C. C., Shiesh, S. C., Chen, S. H., Liu, H. S.,
Lin, Y. S., Wang, S. T., Shyu, H. W. & Yeh, T. M. (2006). Correlation of
serum levels of macrophage migration inhibitory factor with disease severity
and clinical outcome in dengue patients. Am J Trop Med Hyg 74, 142–147.
Chen, H. C., Hofman, F. M., Kung, J. T., Lin, Y. D. & Wu-Hsieh, B. A.
(2007). Both virus and tumor necrosis factor alpha are critical for endothe-
lium damage in a mouse model of dengue virus-induced hemorrhage.
J Virol 81, 5518–5526.
Chen, J., Ng, M. M. & Chu, J. J. (2015). Activation of TLR2 and TLR6 by
dengue NS1 protein and its implications in the immunopathogenesis of
dengue virus infection. PLoS Pathog 11, e1005053.
Cheng, S. B. & Sharma, S. (2015). Interleukin-10: a pleiotropic regulator
in pregnancy. Am J Reprod Immunol 73, 487–500.
Clark, I. A. (2007). The advent of the cytokine storm. Immunol Cell Biol 85,
271–273.
Clyde, K., Kyle, J. L. & Harris, E. (2006). Recent advances in deciphering
viral and host determinants of dengue virus replication and pathogenesis.
J Virol 80, 11418–11431.
Cochrane Group (2012). Cochrane Handbook for Systematic Reviews of
Interventions, version 5. 1. 0. London: Cochrane Group.
Costa, V. V., Fagundes, C. T., Valad~ao, D. F., Cisalpino, D., Dias, A. C.,
Silveira, K. D., Kangussu, L. M., Ávila, T. V., Bonfim, M. R. & other
authors (2012). A model of DENV-3 infection that recapitulates severe
disease and highlights the importance of IFN-g in host resistance to infec-
tion. PLoS Negl Trop Dis 6, e1663.
Cui, L., Lee, Y. H., Kumar, Y., Xu, F., Lu, K., Ooi, E. E.,
Tannenbaum, S. R. & Ong, C. N. (2013). Serum metabolome and lipi-
dome changes in adult patients with primary dengue infection. PLoS Negl
Trop Dis 7, e2373.
Cui, L., Lee, Y. H., Thein, T. L., Fang, J., Pang, J., Ooi, E. E., Leo, Y. S.,
Ong, C. N. & Tannenbaum, S. R. (2016). Serum metabolomics reveals
serotonin as a predictor of severe dengue in the early phase of dengue fever.
PLoS Negl Trop Dis 10, e0004607.
D’Andrea, A., Aste-Amezaga, M., Valiante, N. M., Ma, X., Kubin, M. &
Trinchieri, G. (1993). Interleukin 10 (IL-10) inhibits human lymphocyte
Y. H. Lee, W.-Y. Leong and A. Wilder-Smith
3116 Journal of General Virology 97
interferon gamma-production by suppressing natural killer cell stimulatory
factor/IL-12 synthesis in accessory cells. J Exp Med 178, 1041–1048.
De La Cruz Hernandez, S. I., Puerta-Guardo, H., Flores-Aguilar, H.,
Gonzalez-Mateos, S., López-Martinez, I., Ortiz-Navarrete, V.,
Ludert, J. E. & Del Angel, R. M. (2014). A strong interferon response cor-
relates with a milder dengue clinical condition. J Clin Virol 60, 196–199.
De-Oliveira-Pinto, L. M., Marinho, C. F., Povoa, T. F., de Azeredo, E. L.,
de Souza, L. A., Barbosa, L. D., Motta-Castro, A. R., Alves, A. M.,
Ávila, C. A. & other authors (2012). Regulation of inflammatory chemo-
kine receptors on blood T cells associated to the circulating versus liver che-
mokines in dengue fever. PLoS One 7, e38527.
Del Moral-Hernandez, O., Martínez-Hernandez, N. E., Mosso-Pani,
M. A., Hernandez-Sotelo, D., Illades-Aguiar, B., Flores-Alfaro, E.,
Antonio-Vejar, V. & Leyva-Vazquez, M. A. (2014). Association DENV1
and DENV2 infection with high serum levels of soluble thrombomodulin
and VEGF in patients with dengue fever and dengue hemorrhagic fever. Int
J Clin Exp Med 7, 370–378.
Duyen, H. T., Ngoc, T. V., Ha, D. T., Hang, V. T., Kieu, N. T., Young, P. R.,
Farrar, J. J., Simmons, C. P., Wolbers, M. & Wills, B. A. (2011). Kinetics
of plasma viremia and soluble nonstructural protein 1 concentrations in
dengue: differential effects according to serotype and immune status. J
Infect Dis 203, 1292–1300.
Endy, T. P., Nisalak, A., Chunsuttitwat, S., Vaughn, D. W., Green, S.,
Ennis, F. A., Rothman, A. L. & Libraty, D. H. (2004). Relationship of pre-
existing dengue virus (DV) neutralizing antibody levels to viremia and
severity of disease in a prospective cohort study of DV infection in Thailand.
J Infect Dis 189, 990–1000.
Fink, J., Gu, F. & Vasudevan, S. G. (2006). Role of T cells, cytokines and
antibody in dengue fever and dengue haemorrhagic fever. Rev Med Virol 16,
263–275.
Furuta, T., Murao, L. A., Lan, N. T., Huy, N. T., Huong, V. T., Thuy, T. T.,
Tham, V. D., Nga, C. T., Ha, T. T. & other authors (2012). Association of
mast cell-derived VEGF and proteases in Dengue shock syndrome. PLoS
Negl Trop Dis 6, e1505.
Green, S., Vaughn, D. W., Kalayanarooj, S., Nimmannitya, S.,
Suntayakorn, S., Nisalak, A., Lew, R., Innis, B. L., Kurane, I. & other
authors (1999a). Early immune activation in acute dengue illness is
related to development of plasma leakage and disease severity. J Infect Dis
179, 755–762.
Green, S., Vaughn, D. W., Kalayanarooj, S., Nimmannitya, S.,
Suntayakorn, S., Nisalak, A., Rothman, A. L. & Ennis, F. A. (1999b).
Elevated plasma interleukin-10 levels in acute dengue correlate with disease
severity. J Med Virol 59, 329–334.
Green, S. & Rothman, A. (2006). Immunopathological mechanisms in
dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 19, 429–436.
Guerrero, C. D., Arrieta, A. F., Ramirez, N. D., Rodríguez, L. S.,
Vega, R., Bosch, I., Rodríguez, J. A., Narvaez, C. F. & Salgado, D. M.
(2013). High plasma levels of soluble ST2 but not its ligand IL-33 is associ-
ated with severe forms of pediatric dengue. Cytokine 61, 766–771.
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y.,
Alonso-Coello, P., Schünemann, H. J. & GRADE Working Group
(2008). GRADE: an emerging consensus on rating quality of evidence and
strength of recommendations. BMJ 336, 924–926.
Halstead, S. B. & O’Rourke, E. J. (1977). Antibody-enhanced dengue
virus infection in primate leukocytes.Nature 265, 739–741.
Halstead, S. B., Mahalingam, S., Marovich, M. A., Ubol, S. &
Mosser, D. M. (2010). Intrinsic antibody-dependent enhancement of
microbial infection in macrophages: disease regulation by immune com-
plexes. Lancet Infect Dis 10, 712–722.
Hammond, S. N., Balmaseda, A., Perez, L., Tellez, Y., Saborío, S. I.,
Mercado, J. C., Videa, E., Rodriguez, Y., Perez, M. A. & other authors
(2005). Differences in dengue severity in infants, children, and adults in a
3-year hospital-based study in Nicaragua. Am J Trop Med Hyg 73, 1063–
1070.
Hayes, D. F., Trock, B. & Harris, A. L. (1998). Assessing the clinical impact
of prognostic factors: when is ‘statistically significant’ clinically useful?
Breast Cancer Res Treat 52, 305–319.
Horras, C. J., Lamb, C. L. & Mitchell, K. A. (2011). Regulation of hepato-
cyte fate by interferon-g . Cytokine Growth Factor Rev 22, 35–43.
Houghton-Triviño, N., Salgado, D. M., Rodríguez, J. A., Bosch, I. &
Castellanos, J. E. (2010). Levels of soluble ST2 in serum associated with
severity of dengue due to tumour necrosis factor alpha stimulation. J Gen
Virol 91, 697–706.
Kalayanarooj, S., Vaughn, D. W., Nimmannitya, S., Green, S.,
Suntayakorn, S., Kunentrasai, N., Viramitrachai, W., Ratanachu-
eke, S., Kiatpolpoj, S. & other authors (1997). Early clinical and labora-
tory indicators of acute dengue illness. J Infect Dis 176, 313–321.
Koraka, P., Lim, Y. P., Shin, M. D., Setiati, T. E., Mairuhu, A. T., van
Gorp, E. C., Soemantri, A., Osterhaus, A. D. & Martina, B. E. (2010).
Plasma levels of inter-alpha inhibitor proteins in children with acute dengue
virus infection. PLoS One 5, e9967.
Kumar, Y., Liang, C., Bo, Z., Rajapakse, J. C., Ooi, E. E. &
Tannenbaum, S. R. (2012). Serum proteome and cytokine analysis in a
longitudinal cohort of adults with primary dengue infection reveals predic-
tive markers of DHF. PLoS Negl Trop Dis 6, e1887.
Kurane, I., Innis, B. L., Nimmannitya, S., Nisalak, A., Meager, A.,
Janus, J. & Ennis, F. A. (1991). Activation of T lymphocytes in dengue
virus infections. High levels of soluble interleukin 2 receptor, soluble CD4,
soluble CD8, interleukin 2, and interferon-gamma in sera of children with
dengue. J Clin Invest 88, 1473–1480.
Kurane, I., Innis, B. L., Nimmannitya, S., Nisalak, A., Meager, A. &
Ennis, F. A. (1993). High levels of interferon alpha in the sera of children
with dengue virus infection. Am J Trop Med Hyg 48, 222–229.
Kyle, J. L. & Harris, E. (2008). Global spread and persistence of dengue.
Annu Rev Microbiol 62, 71–92.
Laur, F., Murgue, B., Deparis, X., Roche, C., Cassar, O. & Chungue, E.
(1998). Plasma levels of tumour necrosis factor alpha and transforming
growth factor beta-1 in children with dengue 2 virus infection in French
Polynesia. Trans R Soc Trop Med Hyg 92, 654–656.
Lee, L. K., Earnest, A., Carrasco, L. R., Thein, T. L., Gan, V. C., Lee, V. J.,
Lye, D. C. & Leo, Y. S. (2013). Safety and cost savings of reducing adult
dengue hospitalization in a tertiary care hospital in Singapore. Trans R Soc
Trop Med Hyg 107, 37–42.
Lee, Y. H. & Ooi, E. E. (2013). Molecular biomarkers at the interface of
basic and clinical dengue research. Annals Acad Med 42, 608–610.
Leo, Y. S., Gan, V. C., Ng, E. L., Hao, Y., Ng, L. C., Pok, K. Y.,
Dimatatac, F., Go, C. J. & Lye, D. C. (2013). Utility of warning signs in
guiding admission and predicting severe disease in adult dengue. BMC
Infect Dis 13, 498.
Levy, A., Valero, N., Espina, L. M., Añez, G., Arias, J. & Mosquera, J.
(2010). Increment of interleukin 6, tumour necrosis factor alpha, nitric
oxide, C-reactive protein and apoptosis in dengue. Trans R Soc Trop Med
Hyg 104, 16–23.
Libraty, D. H., Endy, T. P., Houng, H. S., Green, S., Kalayanarooj, S.,
Suntayakorn, S., Chansiriwongs, W., Vaughn, D. W., Nisalak, A. &
other authors (2002a). Differing influences of virus burden and immune
activation on disease severity in secondary dengue-3 virus infections. J Infect
Dis 185, 1213–1221.
Libraty, D. H., Young, P. R., Pickering, D., Endy, T. P., Kalayanarooj, S.,
Green, S., Vaughn, D. W., Nisalak, A., Ennis, F. A. & Rothman, A. L.
(2002b). High circulating levels of the dengue virus nonstructural protein
NS1 early in dengue illness correlate with the development of dengue hem-
orrhagic fever. J Infect Dis 186, 1165–1168.
Cytokines and chemokines as dengue prognosis biomarkers
http://jgv.microbiologyresearch.org 3117
Libraty, D. H., Acosta, L. P., Tallo, V., Segubre-Mercado, E.,
Bautista, A., Potts, J. A., Jarman, R. G., Yoon, I. K., Gibbons, R. V. &
other authors (2009). A prospective nested case-control study of dengue
in infants: rethinking and refining the antibody-dependent enhancement
dengue hemorrhagic fever model. PLoS Med 6, e1000171.
Malavige, G. N., Gomes, L., Alles, L., Chang, T., Salimi, M., Fernando, S.,
Nanayakkara, K. D., Jayaratne, S. & Ogg, G. S. (2013a). Serum IL-10 as a
marker of severe dengue infection. BMC Infect Dis 13, 341.
Malavige, G. N., Jeewandara, C., Alles, K. M. L., Salimi, M., Gomes, L.,
Kamaladasa, A., Jayaratne, S. D. & Ogg, G. S. (2013b). Suppression of
virus specific immune responses by IL-10 in acute dengue infection. PLoS
Negl Trop Dis 7, e2409.
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M.,
Clark, G. M. & Statistics Subcommittee of the NCI-EORTC Working
Group on Cancer Diagnostics (2005). REporting recommendations for
tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2,
416–422.
Modhiran, N., Watterson, D., Muller, D. A., Panetta, A. K., Sester, D. P.,
Liu, L., Hume, D. A., Stacey, K. J. & Young, P. R. (2015). Dengue virus
NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial
cell monolayer integrity. Sci Transl Med 7, 304ra142.
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & PRISMA Group
(2009). Preferred reporting items for systematic reviews and meta-analyses:
the PRISMA statement. PLoS Med 6, e1000097.
Mongkolsapaya, J., Dejnirattisai, W., Xu, X. N., Vasanawathana, S.,
Tangthawornchaikul, N., Chairunsri, A., Sawasdivorn, S.,
Duangchinda, T., Dong, T. & other authors (2003). Original antigenic
sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat
Med 9, 921–927.
Murphy, B. R. & Whitehead, S. S. (2011). Immune response to dengue
virus and prospects for a vaccine. Annu Rev Immunol 29, 587–619.
Narvaez, F., Gutierrez, G., Perez, M. A., Elizondo, D., Nuñez, A.,
Balmaseda, A. & Harris, E. (2011). Evaluation of the traditional and
revised WHO classifications of dengue disease severity. PLoS Negl Trop Dis
5, e1397.
Nguyen, T. H., Lei, H. Y., Nguyen, T. L., Lin, Y. S., Huang, K. J., Le, B. L.,
Lin, C. F., Yeh, T. M., Do, Q. H. & other authors (2004). Dengue hemor-
rhagic fever in infants: a study of clinical and cytokine profiles. J Infect Dis
189, 221–232.
O’Garra, A. & Vieira, P. (2007). T(H)1 cells control themselves by produc-
ing interleukin-10. Nat Rev Immunol 7, 425–428.
OhAinle, M., Balmaseda, A., Macalalad, A. R., Tellez, Y., Zody, M. C.,
Saborío, S., Nuñez, A., Lennon, N. J., Birren, B. W. & other authors
(2011). Dynamics of dengue disease severity determined by the interplay
between viral genetics and serotype-specific immunity. Sci Transl Med 3,
114ra128.
Pal, T., Dutta, S. K., Mandal, S., Saha, B. & Tripathi, A. (2014). Differen-
tial clinical symptoms among acute phase Indian patients revealed signifi-
cant association with dengue viral load and serum IFN-gamma level. J Clin
Virol 61, 365–370.
Potts, J. A. & Rothman, A. L. (2008). Clinical and laboratory features that
distinguish dengue from other febrile illnesses in endemic populations.
Trop Med Int Health 13, 1328–1340.
Perez, A. B., García, G., Sierra, B., Alvarez, M., Vazquez, S.,
Cabrera, M. V., Rodríguez, R., Rosario, D., Martínez, E. & other
authors (2004). IL-10 levels in dengue patients: some findings from
the exceptional epidemiological conditions in Cuba. J Med Virol 73,
230–234.
Rathakrishnan, A., Wang, S. M., Hu, Y., Khan, A. M.,
Ponnampalavanar, S., Lum, L. C., Manikam, R. & Sekaran, S. D.
(2012). Cytokine expression profile of dengue patients at different phases
of illness. PLoS One 7, e52215.
Shresta, S., Kyle, J. L., Snider, H. M., Basavapatna, M., Beatty, P. R. &
Harris, E. (2004). Interferon-dependent immunity is essential for resis-
tance to primary dengue virus infection in mice, whereas T- and B-cell-
dependent immunity are less critical. J Virol 78, 2701–2710.
Soundravally, R., Hoti, S. L., Patil, S. A., Cleetus, C. C.,
Zachariah, B., Kadhiravan, T., Narayanan, P. & Kumar, B. A.
(2014). Association between proinflammatory cytokines and lipid per-
oxidation in patients with severe dengue disease around defervescence.
Int J Infect Dis 18, 68–72.
Srikiatkhachorn, A. & Green, S. (2010).Markers of dengue disease sever-
ity. Curr Top Microbiol Immunol 338, 67–82.
St John, A. L., Rathore, A. P., Raghavan, B., Ng, M. L. &
Abraham, S. N. (2013). Contributions of mast cells and vasoactive
products, leukotrienes and chymase, to dengue virus-induced vascular
leakage. Elife 2, e00481.
Suharti, C., van Gorp, E. C., Dolmans, W. M., Setiati, T. E., Hack, C. E.,
Djokomoeljanto, R. & van der Meer, J. W. (2003). Cytokine patterns dur-
ing dengue shock syndrome. Eur Cytokine Netw 14, 172–177.
Suhrbier, A. & La Linn, M. (2003). Suppression of antiviral responses by
antibody-dependent enhancement of macrophage infection. Trends
Immunol 24, 165–168.
Thein, T. L., Gan, V. C., Lye, D. C., Yung, C. F. & Leo, Y. S. (2013). Utili-
ties and limitations of the World Health Organization 2009 warning signs
for adult dengue severity. PLoS Negl Trop Dis 7, e2023.
Tricou, V., Minh, N. N., Farrar, J., Tran, H. T. & Simmons, C. P. (2011).
Kinetics of viremia and NS1 antigenemia are shaped by immune status and
virus serotype in adults with dengue. PLoS Negl Trop Dis 5, e1309.
Tsai, C.-Y., Lee, I.-K., Lee, C.-H., Yang, K. D. & Liu, J.-W. (2013a). Com-
parisons of dengue illness classified based on the 1997 and 2009 World
Health Organization dengue classification schemes. J Microbiol Immunol
Infect 46, 271–281.
Tsai, T. T., Chuang, Y. J., Lin, Y. S., Wan, S. W., Chen, C. L. & Lin, C. F.
(2013b). An emerging role for the anti-inflammatory cytokine interleukin-
10 in dengue virus infection. J Biomed Sci 20, 40.
Ubol, S., Phuklia, W., Kalayanarooj, S. & Modhiran, N. (2010). Mecha-
nisms of immune evasion induced by a complex of dengue virus and preex-
isting enhancing antibodies. J Infect Dis 201, 923–935.
van de Weg, C. A., Pannuti, C. S., van den Ham, H. J., de Araújo, E. S.,
Boas, L. S., Felix, A. C., Carvalho, K. I., Levi, J. E., Romano, C. M. &
other authors (2014). Serum angiopoietin-2 and soluble VEGF receptor 2
are surrogate markers for plasma leakage in patients with acute dengue virus
infection. J Clin Virol 60, 328–335.
Vaughn, D. W., Green, S., Kalayanarooj, S., Innis, B. L.,
Nimmannitya, S., Suntayakorn, S., Endy, T. P., Raengsakulrach, B.,
Rothman, A. L. & other authors (2000). Dengue viremia titer, antibody
response pattern, and virus serotype correlate with disease severity. J Infect
Dis 181, 2–9.
Wang, L., Chen, R. F., Liu, J. W., Yu, H. R., Kuo, H. C. & Yang, K. D.
(2007). Implications of dynamic changes among tumor necrosis factor-a
(TNF-a), membrane TNF receptor, and soluble TNF receptor levels in
regard to the severity of dengue infection. Am J Trop Med Hyg 77, 297–302.
WHO (1986). Dengue Haemorrhagic Fever: Diagnosis, Treatment, Prevention
and Control, 1st edn. Geneva: World Health Organization.
WHO (1997). Dengue Haemorrhagic Fever: Diagnosis, Treatment, Prevention
and Control, 2nd edn. Geneva: World Health Organisation.
WHO (2009). Dengue: Guidelines for Diagnosis, Treatment Prevention and
Control. Geneva: World Health Organization.
Wells, , G., Shea, B., O’Connell, D., Peterson, J., Welch, V., Losos, M. &
Tugwell, P. (2013). The Newcastle-Ottawa Scale (NOS) for assessing the
quality of nonrandomised studies in meta-analyses. Ottawa, ON: Ottawa
Y. H. Lee, W.-Y. Leong and A. Wilder-Smith
3118 Journal of General Virology 97
Hospital Research Institute. http://www.ohri.ca/programs/clinical_epide-
miology/oxford.asp.
Wilder-Smith, A. & Massad, E. (2016). Age specific differences in efficacy
and safety for the CYD-tetravalent dengue vaccine. Expert Rev Vaccines 15,
437–441.
Yacoub, S. & Wills, B. (2014). Predicting outcome from dengue. BMC
Med 12, 147.
Zapata, J. C., Cox, D. & Salvato, M. S. (2014). The role of platelets
in the pathogenesis of viral hemorrhagic fevers. PLoS Negl Trop Dis 8,
e2858.
Cytokines and chemokines as dengue prognosis biomarkers
http://jgv.microbiologyresearch.org 3119
